uniQure NV (LTS:0EE0)
$ 6.32 -0.73 (-10.35%) Market Cap: 312.44 Mil Enterprise Value: -55.20 Mil PE Ratio: 0 PB Ratio: 5.60 GF Score: 73/100

Uniqure NV at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript

Mar 31, 2022 / 12:00PM GMT
Release Date Price: $18.15
Debjit Chattopadhyay
Guggenheim Securities - Analyst

Good morning and thank you for joining Guggenheim's genomic medicines and rare disease conference. I am Debjit, representing the Guggenheim therapeutics team. And it is my privilege to host uniQure's Chief Executive Officer, Matt Kapusta, for a fireside chat to kick off this two-day event. Thank you for your time, Matt.

Matt Kapusta
UniQure NV - CEO

Thanks for having us, Debjit.

Questions & Answers

Debjit Chattopadhyay
Guggenheim Securities - Analyst

Good morning. And so maybe we can start it off with sort of a broad thought process question here. You've been the CEO of uniQure for a little over five years now. How would you reflect on the company's progress as well as challenges during this time? And from driving shareholder value for the next three to four years or next one to three years, what should we be focused on?

Matt Kapusta
UniQure NV - CEO

Yes, it's a great question. I think that we've made

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot